Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) EBITDA Margin (2020 - 2026)

Rani Therapeutics Holdings' EBITDA Margin history spans 5 years, with the latest figure at 488.23% for Q1 2026.

  • On a quarterly basis, EBITDA Margin rose 649607.0% to 488.23% in Q1 2026 year-over-year; TTM through Mar 2026 was 1092.96%, a 318154.0% increase, with the full-year FY2025 number at 2345.99%, up 284020.0% from a year prior.
  • EBITDA Margin came in at 488.23% for Q1 2026, up from 584.19% in the prior quarter.
  • The five-year high for EBITDA Margin was 488.23% in Q1 2026, with the low at 6984.3% in Q1 2025.
  • Historically, EBITDA Margin has averaged 2377.95% across 3 years, with a median of 1019.62% in 2025.
  • Biggest five-year swings in EBITDA Margin: soared 87087bps in 2025 and later soared 649607bps in 2026.
  • Year by year, EBITDA Margin stood at 1455.06% in 2024, then surged by 60bps to 584.19% in 2025, then grew by 16bps to 488.23% in 2026.
  • Business Quant data shows EBITDA Margin for RANI at 488.23% in Q1 2026, 584.19% in Q4 2025, and 6984.3% in Q1 2025.